Report: Injectable antibodies top growth chart

10/11/2007 | NYTimes.com

Sales of injectable monoclonal antibodies will grow 14% annually from 2006 to 2012, preserving their status as the fastest-growing class of drugs during the next five years, market analyst Datamonitor says in its latest report. Antibody-based drugs already are popular for the treatment of cancer and rheumatoid arthritis and currently generate $20 billion in global revenue.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY